Treatment-resistant depression, how TMS therapy actually works, how to verify your insurance, what to expect during your first session. Written for patients and families.
How Medicare covers TMS for major depression through regional Local Coverage Determinations (LCDs) rather than a single national policy — the typical LCD criteria, how jurisdiction is determined, and how the 2026 CMS-0057-F prior-authorization rule applies.
How clinicians approach TMS maintenance after a successful acute course, where no schedule is FDA-cleared — the three models seen in practice (no maintenance, scheduled tapering boosters, and symptom-triggered boosters) and the factors that point a patient toward each.
Why transcranial magnetic stimulation is a reasonable, lactation-compatible option for postpartum depression when first-line treatment falls short or systemic medication is declined — an off-label use of an FDA-cleared therapy that acts focally, with nothing transferred into breast milk.
What the 2023 Pigott reanalysis of the STAR*D trial found — a cumulative remission rate near 35% rather than the originally published 67% after four sequential antidepressant strategies — and why that revision moves TMS earlier in the treatment pathway.
What the patient experience looks like inside our Anaheim treatment room — and why a coordinated outpatient setting, deliberately unlike a hospital department, reduces friction for patients beginning a course of TMS for treatment-resistant depression.
What to do when TMS prior authorization is denied — why most denials are documentation gaps rather than clinical rejections, and how the three appeal levels (peer-to-peer, formal written appeal, and external independent review) reverse a meaningful share of them.
What patients actually experience during and after TMS — mild, transient scalp discomfort at the treatment site, the rare seizure risk in numerical terms (fewer than 1 in 60,000 sessions), and why there is no sedation, systemic drug exposure, or documented cognitive impairment.
Where transcranial magnetic stimulation fits for PTSD after first-line treatments fall short — an off-label use of an FDA-cleared therapy, the controlled-trial and meta-analysis evidence, and why the strongest signal appears in patients whose PTSD co-occurs with depression.
Why Healing TMS Clinic was built as a TMS-first practice — Dr. Padmini Shamasundara's 27 years in psychiatry, and the case for keeping evaluation, TMS treatment, and insurance coordination inside one practice rather than referring treatment-resistant patients outward.
Why intermittent theta-burst stimulation (iTBS) and standard 10 Hz rTMS produce equivalent response and remission rates in major depression — the THREE-D non-inferiority trial, a decade of supporting evidence, and why iTBS runs about a third as long per session.
A step-by-step walkthrough of prior authorization for TMS — the clinical criteria payers review, the documentation packet the clinic assembles, and the typical 5-to-15-business-day timeline for commercial and Medicare Advantage plans.
How long a full TMS course takes for major depression — roughly six to nine weeks of weekday sessions, about 20 minutes per visit for iTBS or 40 for standard 10 Hz rTMS — plus what makes a course shorter or longer and how the taper works.
Insurance verification takes about two minutes. We'll tell you whether your plan covers TMS for treatment-resistant depression and what your cost will be — before you book anything.
Monday–Friday, 9:00 AM – 5:00 PM